Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
04 Dezembro 2023 - 10:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX) today announced the appointment of Michael W. Kalb
as its Executive Vice President and Chief Financial Officer,
effective on January 1, 2024. Mr. Kalb will report directly to the
Company’s Chief Executive Officer and will serve as a member of the
Company's executive leadership team. Mr. Kalb's distinguished
career in finance spans over three decades in the pharmaceutical
and financial services sector. He succeeds Ms. Alicia Grande, who
will retire from the Company at the end of this year.
“Allie has been an invaluable contributor
through a tremendous period of growth and evolution for Catalyst,”
stated Patrick J. McEnany, Catalyst's Chairman and CEO. “We thank
her for her dedicated service as CFO and for her guiding hand over
the last 16 years. We are pleased that Allie will continue to
assist the company as an advisor through a transition period ending
on December 31, 2024.”
“We are delighted to welcome Michael to our
team, an accomplished pharmaceutical executive with a wealth of
experience in finance, capital allocation, strategic transactions,
and operational management,” Mr. McEnany continued. “His profound
industry acumen and proven value-creation track record are assets
we look forward to leveraging to drive transformative contributions
that will enhance our Company's near and long-term growth.”
“This is an exciting time to be joining Catalyst
during a pivotal period in the Company's growth, expansion, and
transformation,” commented Mr. Kalb. “I look forward to actively
collaborating with the Catalyst team to propel our initiatives,
leverage our strengths, and capitalize on the opportunities to
contribute to the overall progress of the business.”
Mr. Kalb brings extensive financial expertise to
Catalyst, backed by his distinguished career in senior financial
leadership roles. Before joining the Company, Mr. Kalb served as
Chief Financial Officer at Impel Pharmaceuticals, Inc., and
previously served as Executive Vice President and Chief Financial
Officer of CinCor Pharma, Inc. Further, Mr. Kalb served as Senior
Vice President and Chief Financial Officer of Amarin Corporation
plc, where he contributed to its significant revenue growth,
increased market capitalization, and successfully led multiple
financing rounds of varying sizes and structures. Before his tenure
at Amarin, Mr. Kalb served in several financial senior management
positions at Taro Pharmaceutical Industries, Ltd., including as
Group Vice President and Chief Financial Officer, and as a Director
in the Accounting and Financial Consulting Group of Huron
Consulting Group Inc. His experience also includes over ten years
of public accounting experience, principally at Ernst and Young.
Mr. Kalb holds a B.S. in Accounting from the State University of
New York at Albany, School of Business. Mr. Kalb is a certified
public accountant.
Additionally, we are pleased to announce that
effective on January 1, 2024, Dr. Steven Miller will be promoted to
Executive Vice President, Chief Operating and Scientific Officer
and Jeffrey Del Carmen will be promoted to Executive Vice
President, Chief Commercial Officer.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for AGAMREE® (vamorolone) oral suspension 40 mg/mL, a
novel corticosteroid treatment for Duchenne Muscular
Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26,
2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE, please visit https://www.agamree.com/.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2022 and its other
filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024